🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05300997
Recruiting Observational

Translational Immunodiagnostics in Stroke (TrImS)

NCT05300997 · tracked via the Priya Life Science China tracker
Sponsor
The University of Hong Kong
Phase
Observational
Started
2022-05-01
Last updated
2026-05-11

Condition(s) studied

Acute Ischemic StrokeHaemorrhagic StrokeTransient Ischemic AttacksCardioembolic StrokeLarge-Artery Atherosclerosis (Embolus/Thrombosis)Small Vessel DiseaseStroke of Other Determined EtiologyStroke of Undetermined EtiologyAtrial FibrillationStroke of Anterior Cerebral ArteryStroke of Middle Cerebral ArteryStroke of Basilar Artery

Investigational drug(s) / intervention(s)

Biomarker blood draw and saliva collection

Biomarker blood draw and saliva collection: Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)

Study summary

In adult patients presenting to emergency departments within 24 hours of symptom onset with suspected acute stroke, we aim:

1. to identify early brain- and pathology-specific circulating, whole blood, plasma and serum panorOmic biomarkers that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis.
2. to identify early brain- and pathology-specific, panorOmic biomarkers in saliva that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis.
3. to derive biomarker platforms of models for early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis
4. to validate these models in independent and external datasets

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients eligible for enrolment include: * Adults ≥18 years of age. * Suspected acute stroke. Defined as either FAST-positive, or LAPSS-positive or ROSIER\>0 * Within 24 hours of symptom onset. * Informed consent. * Control subjects will be drawn from two groups: * Non-neurologic patients who are matched with TIA and stroke cases (AIS, HS) for age, race, gender and smoking plus one or more of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidaemia. * Relatives or accompanying friends. * Note that we will include and collect samples from the following cases if they present as suspected stroke and are recruited \<24 hours from symptom onset. * Any central nervous system infection, i.e. meningitis or encephalitis in the past 30 days * Any form of head trauma, stroke or intracranial haemorrhage in the past 30 days * Known primary or metastatic cancer involving the brain * Active cancer is defined as a diagnosis of cancer, within 6 months before enrollment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer. * Autoimmune diseases: such as lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis * Active infectious diseases (e.g. HIV/AIDS, hepatitis C) * Major surgery within three months prior to the index event Exclusion Criteria: * Clear onset of acute symptoms \>24 hours.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hong Kong University Hong Kong China Recruiting

More The University of Hong Kong trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05300997 on ClinicalTrials.gov ↗ ← All trials in China